Results 1 to 10 of about 710,958 (307)

Chinese Expert Consensus on Second-line Treatment for Non-small Cell Lung Cancer with Negative Driver Gene Mutations

Chinese Journal of Lung Cancer
For advanced non-small cell lung cancer (NSCLC) patients with negative driver gene mutations, chemotherapy has always been the standard treatment option, and immune checkpoint inhibitors (ICIs) provide other treatment option for these patients.
Expert Committee on Non-small Cell Lung Cancer of the Chinese Society of Clinical Oncology
doaj   +2 more sources

Chinese Expert Consensus on the Standardized Diagnosis and Treatment of 
Non‑small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2024 Edition)

Chinese Journal of Lung Cancer
The standard clinical practice of managing the non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations was elaborated in Chinese expert consensus on non‑small cell lung cancer with EGFR exon ...
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer Committee
doaj   +2 more sources

Usability and Feasibility of Chest Perfusion Computed Tomography in Differentiating Small Cell Lung Cancer and Non-Small Cell Lung Cancer

Archives of Basic and Clinical Research
Objective: We aimed to investigate to usability and feasibility of perfusion computerized tomography (PCT) in differentiating small cell lung cancer (SCLC) from non-small cell lung cancer (NSCLC).
Ömer Özyiğit, Suat Eren
doaj   +2 more sources

Angiogenesis and non-small cell lung cancer

Lung Cancer, 2000
Lung cancer is the commonest cause of cancer death in the western world. Recent evidence suggests that angiogenesis is related to poor prognosis in many solid tumours including non-small cell lung cancer. Angiogenesis is controlled by a complex interaction between growth and apoptotic factors, proteases and adhesion molecules.
Cox, G., Jones, J. L., Walker, R. A., Steward, W. P., O'Byrne, Kenneth J.   +4 more
openaire   +4 more sources

Afatinib treatment in advanced non-small cell lung cancer

Lung Cancer: Targets and Therapy, 2011
Jane L Hurwitz, Paula Scullin, Lynn CampbellDepartment of Medical Oncology, Northern Ireland Cancer Centre, Belfast, UKAbstract: Despite some recent advances in the management of advanced non-small cell lung cancer (NSCLC), prognosis for these patients ...
Hurwitz JL, Scullin P, Campbell L
doaj   +1 more source

Non–Small Cell Lung Cancer [PDF]

Journal of the National Comprehensive Cancer Network, 2012
Most patients with non-small cell lung cancer (NSCLC) are diagnosed with advanced cancer. These guidelines only include information about stage IV NSCLC. Patients with widespread metastatic disease (stage IV) are candidates for systemic therapy, clinical trials, and/or palliative treatment.
David S, Ettinger, Wallace, Akerley, Hossein, Borghaei, Andrew C, Chang, Richard T, Cheney, Lucian R, Chirieac, Thomas A, D'Amico, Todd L, Demmy, Apar Kishor P, Ganti, Ramaswamy, Govindan, Frederic W, Grannis, Leora, Horn, Thierry M, Jahan, Mohammad, Jahanzeb, Anne, Kessinger, Ritsuko, Komaki, Feng-Ming, Kong, Mark G, Kris, Lee M, Krug, Inga T, Lennes, Billy W, Loo, Renato, Martins, Janis, O'Malley, Raymond U, Osarogiagbon, Gregory A, Otterson, Jyoti D, Patel, Mary C, Pinder-Schenck, Katherine M, Pisters, Karen, Reckamp, Gregory J, Riely, Eric, Rohren, Scott J, Swanson, Douglas E, Wood, Stephen C, Yang, Miranda, Hughes, Kristina M, Gregory   +35 more
openaire   +4 more sources

Chinese Expert Consensus on Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2023 Edition)

Chinese Journal of Lung Cancer, 2023
With the development of precision diagnosis and treatment for non-small cell lung cancer (NSCLC), the epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations, as a rare subset of EGFR mutaions, have gradually attracted attention ...
Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee
doaj   +1 more source

LncRNAs in Non-Small-Cell Lung Cancer [PDF]

Non-Coding RNA, 2020
Lung cancer is associated with a high mortality, with around 1.8 million deaths worldwide in 2018. Non-small-cell lung cancer (NSCLC) accounts for around 85% of cases and, despite improvement in the management of NSCLC, most patients are diagnosed at advanced stage and the five-year survival remains around 15%.
Lucy Ginn, Lei Shi, Manuela La Montagna, Michela Garofalo   +3 more
openaire   +5 more sources

Non-small cell lung cancer [PDF]

Vnitřní lékařství, 2017
Non-small cell lung cancer (NSCLC) represents 80 % of diseases considering all patients with lung cancer. NSCLC comprises all histological types except for the small cell cancer. The treatment is chosen based on a clinical stage, morphological diagnosis and performance status of patients. In the low clinical stages a surgical solution is indicated.
Jana, Skřičková, Bohdan, Kadlec, Ondřej, Venclíček   +2 more
openaire   +2 more sources

Expert Consensus on Prevention and Treatment of COVID-19 Infection in Patients with Lung Cancer

Chinese Journal of Lung Cancer, 2023
Corona virus disease 2019 (COVID-19) infection has become a major public health issue affecting human health. The main goal of epidemic prevention and control at the current stage in China is to “protect people’s health and prevent severe cases ...
Non-small Cell Lung Cancer Expert Committee of Chinese Society of Clinical Oncology, China Medical Education Association   +1 more
doaj   +1 more source